Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses
© Pham et al. 2016
Received: 8 February 2016
Accepted: 19 April 2016
Published: 30 April 2016
Recommended regimens for HIV-positive individuals include the co-administration of dolutegravir (DTG) with two reverse transcriptase inhibitors (RTIs). Although rare, emerging resistance against DTG is often associated with the R263K substitution in integrase. In-vitro-selected R263K was associated with impaired viral replication capacity, DNA integration, and integrase strand-transfer activity, especially when accompanied by the secondary mutation H51Y. Given the reduced fitness of RTI-resistant viruses, we investigated potential impacts on viral replication of combining R263K and H51Y/R263K with major RTI-resistance substitutions including K65R, L74V, K103N, E138K, and M184I/V.
We combined the R263K or H51Y/R263K with RTI-resistance mutations into the proviral plasmid pNL4.3 and measured the resulting viral infectiousness, replication capacity, and ability to integrate viral DNA into host cells. Infectiousness was determined by luciferase assay in TZM-bl cells. Replicative capacity was monitored over 7 days and viral DNA integration was studied by real-time Alu-qPCR in PM1 cells. We found that viral infectiousness, replication capacities and integration levels were greatly reduced in triple mutants, i.e. H51Y/R263K plus a RT mutation, and moderately reduced in double mutants, i.e. R263K plus a RT mutation, compared to wild-type and single RT-mutant viruses.
Our findings help to explain the absence of RTI mutations in individuals who experienced DTG-treatment failure.
Current antiretroviral (ARV) drugs for treatment of human immunodeficiency virus (HIV) infection include entry inhibitors, protease inhibitors (PIs), nucleoside/non-nucleoside reverse-transcriptase inhibitors (NRTIs/NNRTIs) and integrase strand-transfer inhibitors (INSTIs). In the later class, dolutegravir (DTG) is the most potent drug and can be used without a boosting agent . Unlike raltegravir (RAL) and elvitegravir (EVG), DTG has a higher barrier to resistance, and minimal drug–drug interactions [1, 2]. First-line treatment failure in patients receiving a once daily dose of 50 mg of DTG seems mainly due to non-adherence. Emergence of drug resistance against DTG has not been observed after first-line therapy [3–5]. In second-line treatment of INSTI-naïve patients, a R263K mutation commonly emerged but this substitution causes only about a twofold change in IC50, suggesting that the impact on DTG susceptibility is very low. The absence of clinical impact of the R263K mutation has meant that patients harbouring this substitution might be able to remain on DTG therapy [1, 6].
We previously showed that R263K-containing viruses possess modestly reduced viral replication capacity (about 70 % compared to WT) [7, 8]. The R263K substitution was also selected in vitro, and this was followed by the appearance of such secondary substitutions as H51Y, M50I, and E138K [7–10]. However, none of the latter could compensate for the loss in replicative capacity conferred by R263K and, in fact, had the effect of further decreasing viral replication, integrase strand-transfer activity and levels of integrated DNA, even though the addition of H51Y to R263K increased resistance to DTG to about sevenfold, as measured by the PhenoSense® Integrase Replication Assay (7–10). Similar impacts on viral replicative capacity and DTG resistance in tissue culture and biochemical assays were observed when the E138K or M50I substitutions were introduced into R263K viruses. The H51Y/R263K and M50I/R263K viruses may confer similar levels of DTG resistance (about sevenfold resistance against DTG as measured in TZM-bl cells by luciferase assay) while the level of resistance is only about 4.3-fold for the E138K/R263K virus [7, 8, 10].
This is in contrast to the RAL and EVG resistance pathways, in which secondary mutations commonly restored viral replication capacity while, at the same time, adding to the level of drug resistance conferred by initially selected mutations [11–13]. The absence of compensatory secondary mutations for R263K is also consistent with the observation that many major RAL- and EVG-resistance substitutions such as G140S, Q148R, E92Q, N155H and Y143R are incompatible with the simultaneous presence of R263K in terms of both integrase strand-transfer activity and viral replication capacity . In addition, the emergence of R263K as a secondary substitution has been documented in tissue culture under EVG selection pressure as well as in a Phase two clinical trial of the antiviral activity of EVG . More recently, we have shown that the T66I/R263K combination severely impaired both integrase strand-transfer activity and viral replicative capacity. The T66I/R263K virus was slightly more susceptible to DTG when viruses containing R263K alone were studied but highly resistant to EVG, which explains the emergence of this combination with EVG but not DTG .
DTG is commonly used in treatment together with abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC) in ARV-naïve patients. However, the combined effects of DTG- and RT-resistance mutations have not been well studied until now, although it is known that the combination of M184I/V and R263K in the same virus further decreased viral replication compared to either mutation alone and no DTG or lamivudine cross-class resistance was observed . Now, we have studied the effect of R263K or H51Y-R263K in the presence of other clinically relevant RT mutations, i.e. K65R, L74V, K103N, E138K, and M184I/V. Of the above, K103N is a major mutation associated with resistance to efavirenz and etravirine; both NNRTIs are known to reduce plasma levels of DTG, thereby limiting their use in co-administration with DTG [17, 18]. The E138K substitution in RT has been selected in patients treated with rilpivirine and efavirenz and has resulted in cross-resistance to NNRTIs. Each of K65R, L74V and M184I/V are major NRTI-related mutations [17, 18]. Tenofovir, ABC, lamivudine and didanosine can select for K65R, while lamivudine and emtricitabine select for M184I/V. In the phase 3 102 and 103 clinical studies of a once daily pill of EVG/cobicistat/FTC/TFV, the K65R and M184I/V substitutions were detected, separately or in combination, before the emergence of IN mutations in some patients undergoing treatment failure [19, 20]. L74V has been selected by didanosine and ABC and can confer high-level resistance against these drugs [17, 18].
The addition of DTG-resistance substitutions reduces viral infectiousness in viruses containing the K65R, L74V, K103N, E138K or M184V/I reverse transcriptase mutations
Comparison of RT and p24 assays for normalization of viral infectivity in TZM-bl cells
EC50 (ng p24)
Relative fold decrease in infectivity
95 % Confidence intervals
Relative fold decrease in infectivity
95 % Confidence intervals
Combining DTG- and RTI-resistance mutations reduces viral replicative capacity
Integration capacity of DTG- and RTI-resistant viruses
Current HIV treatment guidelines for first line therapy favor the use of an INSTI together with two NRTIs. In treatments based on the use of RAL or EVG, the co-existence of NRTI and INSTI resistance mutations has been reported in patients experiencing therapeutic failure [19–21]. Most commonly, mutations at N155H and Q148H/R have been observed in combination with M184I/V or less often with K65R. In some of these cases, both K65R and M184V/I have co-emerged with integrase mutations. Fitness defects were also observed for viruses containing these RAL/EVG-resistance mutations together with RT mutations in vitro in the absence of drugs [22, 23]. In contrast, neither DTG nor NRTI resistance has been reported until now in treatment-naïve patients who received DTG plus NRTI treatment. Given that the R263K substitution has been reported in some INSTI-naïve patients in the SAILING study and in tissue culture selections, we aimed to investigate the effects of R263K and its secondary mutation H51Y together with major RTI-resistance substitutions at positions K65R, L74V, K103N, E138K, and M184I/V, in terms of viral replication and integration capacity in the absence of drugs.
First, our study confirmed previous observations on the decrease of viral replication in viruses containing both M184I/V plus R263K . We also confirmed the deficits caused by R263K together with other RTI mutations, i.e. K65R, L74V, K103N, and E138K. However, small changes in the results of infectivity assays may or may not result in differences in infectivity in vivo. Compared to WT virus, the R263K substitution as well as some other major mutations E92Q, Q148R and N155H, reported in the RAL- and/or EVG-resistance pathways, can emerge from a single nucleotide change in most HIV-1 strains. Each of these mutations led to a decrease in viral replicative fitness (less than sevenfold) and integrase strand-transfer activity (less than threefold). However, the levels of resistance associated with these various substitutions for different INSTIs varied considerably. For example, N155H virus caused sixfold and fivefold decreases in susceptibility to RAL and EVG and E92Q conferred more than a 50-fold decrease in EVG susceptibility. Similar sixfold–sevenfold levels of resistance to RAL and EVG have been reported for Q148R virus . In contrast, the common M184V mutation develops rapidly in patients failing lamivudine (3TC) therapy. Although this mutation alone confers up to 100-fold–1000-fold less susceptibility to 3TC, regimens containing this drug have been shown to maintain efficacy in the treatment of HIV-1, perhaps because the M184V mutation is associated with a loss of replicative fitness and increased fidelity of RT activity . Nevertheless, the combination of M184V with K65R has caused virological failures in patients receiving regimens containing two N(t)RTIs, 3TC and tenofovir .
On the other hand, R263K is more commonly detected in HIV-positive individuals who experience treatment failure with DTG even though this substitution only modestly decreases DTG susceptibility (about twofold) as well as HIV-1 replication capacity. This raises the question as to why this substitution is not more commonly observed in clinical settings since its effect on viral fitness is insufficient on its own to explain its absence in most individuals failing DTG-based regimens. One possibility is that viruses that contain R263K and other resistance mutations, e.g. H51Y, are so impaired in replication capacity that they cannot be detected by ordinary Sanger sequencing. Another possibility is that DTG may reach anatomical compartments that are not susceptible to other inhibitors, effectively preventing the emergence of R263K and other substitutions; this possibility is supported by recent reports of persistent HIV replication under suppressive ARV therapy [1, 26].
A related question is why the R263K substitution that confers low-level resistance to DTG is selected at all. The answer is probably that R263K does confer a higher level of resistance against DTG as a single substitution than does any of the resistance mutations associated with RAL or EVG (1). This is fortuitous for the use of DTG even in patients who are not adherent to therapy, especially because the R263K substitution does not seem to be able to co-exist together with mutations at positions 143 and 148 that are frequently observed in patients who have failed therapy with RAL or EVG (14). Secondary resistance mutations usually follow after primary mutations and can both compensate for the loss of viral replication caused by the initial mutation while also resulting in higher levels of drug resistance . However, no secondary mutation for DTG can compensate in this fashion [7, 8, 10]. We previously demonstrated that the secondary mutation H51Y developed after the emergence of R263K in vitro and caused a higher level of resistance against DTG, about 16-fold in TZM-bl cells and sevenfold in the PhenoSense® Integrase Replication assay. H51Y also has a further detrimental effect on viral replication capacity. The current study also shows that this replication deficit is further exacerbated in the presence of different RT resistance mutations, helping to explain the absence of resistance to both DTG and RTIs in first-line therapy.
K103N is a very common NNRTI mutation that only minimally affects viral replication in the absence of drug pressure [27, 28]. The addition of R263K to K103N caused only a small loss in viral replication capacity compared to K103N alone. L74V is associated with a reduced replicative capacity of HIV-1 of about 11 % compared to WT [29, 30]. In our study, decreased replication was also observed with the R263K-L74V virus and this was greatly exacerbated by the additional presence of H51Y. Similar results were obtained with K103N together with R263K/H51Y, with no detection of p24 at days 3 and 7 p.i. Our data show that differences in viral replication in the presence of different resistance mutation combinations may not only be due to possible additive effects but may also reflect possible interactions between RTI- and DTG-resistance mutations. The addition of R263K to viruses containing M184I or M184V, K65R, and E138K yielded fewer viruses that were replication competent than when only single RT mutations were studied. And these differences were further magnified in the presence of H51Y. Possibly as well, the presence of some triple combination mutations may alter interactions between RT and IN, leading to a loss of viral replication and/or generation of non-viable viruses. In the presence of drug pressure, it may be very difficult for HIV-1 to develop all of these mutations in IN and RT at the same time. These findings are consistent with earlier results that the emergence of M184I was delayed in the presence of R263K under lamivudine drug pressure and that the M184I substitution was detected in the case of the H51Y/R263K virus .
Here we also report on the integration capacity of the mutational combinations studied in PM1 cells in comparison to that of WT virus and viruses containing only single RT mutations. Double mutant viruses with RT and R263K integrated less efficiently than either viruses with single RT mutations or WT whereas DNA integration levels in almost all triple mutant viruses were very low or undetectable. Although small differences in integration levels were observed for single RT mutants and double R263K-RT mutants, these were not significant (Student’s t test, P values >0.05), whereas statistical significance was achieved for L74V versus R263K-L74V (Student’s t test, P = 0.03) and M184I versus R263K-M184I (Student’s t test, P = 0.05). In addition, triple mutants bearing the H51Y/R263K-RT mutations resulted in either undetectable integration levels (in cases of H51Y/R263K plus single substitutions K103N, E138K or M184I, Fig. 3c–e) or levels of integration that were statistically inferior to those attained with the single RT mutants (P ≤ 0.05). L74V and M184I are associated with resistance against ABC, which is co-formulated with DTG and lamivudine in a single daily pill; these results suggest that this combination may provide an advantage in regard to pathways leading to drug resistance.
Our integration data, however, did not always directly correlate with the infectivity data (Fig. 1a). For example, H51Y/R263K-K65R triple mutants resulted in appreciable levels of integration that were comparable with those observed with the double mutant R263K-K65R virus (Student’s t test, P = 0.2), whereas the same H51Y/R263K-K65R combination of substitutions attenuated infectivity by 7.8-fold compared to the R263K-K65R combination that only caused a 1.7-fold decrease (Fig. 1a). Although both assays demonstrated a tendency for the triple mutants to be more impaired in both integration and infectivity than the double mutants, some discrepancies in the extent of the impairment as measured in these various assays clearly exist. This may be due to the fact that integration levels were measured using a single viral inoculum whereas the infectivity assays used virus at various titers. In addition, there may be differences between the susceptibilities of different cell lines to becoming infected by the different viruses that were employed. Indeed, integration was necessarily measured in PM1 cells, which support productive HIV-1 replication, whereas the TZM-bl cells used in the infectivity assay do not support multiple cycles of active replication. It is well established that different methods can yield different results in regard to infectivity and resistance assays .
Since integration is important for virus to establish latent reservoirs in host cells, we conjecture that the diminution in levels of integration associated with resistance to DTG may have consequences for the size of the viral reservoir. Further studies on the capacity of latency reservoirs to be established in patients with DTG-resistant viruses or in patients treated with DTG will provide important information on long-term DTG treatment efficacy .
DTG- and RTI-containing viruses are associated with significant loss of viral fitness and DNA integration capacity. This could help to explain the successful use of DTG in treatment of HIV in co-administration with two-NRTI backbones ABC/TDF or FTC/TDF. Our results provide additional information to explain the absence of clinically relevant resistance to DTG when used in combination first-line therapy.
Cells and reagents
TZM-bl and 293T cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM). PM1 cells were cultured in Roswell Park Memorial Institute Medium (RPMI). Cell culture media were supplemented with 10 % fetal bovine serum (FBS), 2 mM l-glutamine, 50 U/ml penicillin, and 50 µg/ml streptomycin and incubated at 37 °C under 5 % CO2.
Generation of infectious HIV-1 stocks
pNL4.3, pNL43R263K, pNL4.3H51Y/R263K, pNL4.3M184I, pNL4.3M184V, pNL4.3R263K-M184I, pNL4.3R263K-M184V, pNL4.3K65R, pNL4.3L74V, pNL4.3K103N, and pNL4.3E138K were previously constructed using site-directed mutagenesis [16, 32, 33]. Similar methods were employed to produce these plasmids: pNL4.3R263K-K65R, pNL4.3H51Y/R263K-K65R, pNL4.3R263K/L74V, pNL4.3H51Y-R263K/L74V, pNL4.3R263K-K103N, pNL4.3H51Y/R263K-K103N, pNL4.3R263K-E138K, pNL4.3H51Y/R263K-E138K, pNL4.3H51Y/R263K-M184I, and pNL4.3H51Y/R263K-M184V. The primer sequences used for PCR site-directed mutagenesis were previously described [8, 9]. All clones that were generated after transformation were purified and sequenced to confirm the presence of expected mutations and have no contamination. To produce infectious homogenous viruses, 12.5 µg of each plasmid DNA purified from maxi cultures that were themselves initiated from a single bacterial clone was transfected into 293T cells using Lipofectamine 2000 (Invitrogen). Fresh medium was added at 4 h.p.i. Culture supernatants containing single cycle HIV virions were collected at 48 h post transfection and passed through a 0.45-µm filter. Virus stocks were aliquoted into small volumes of 500 µl and stored at −80 °C. Freshly thawed virus stocks were used for every experiment and virus stocks left after each usage were discarded and never used again. Quantification of viruses was performed using p24 and RT assays as described previously [8, 9].
HIV-1 infectivity assay
HIV-1 infectivity studies were performed by luciferase assay and by short-term infection of TZM-bl reporter cells. Thirty thousand TZM-bl cells/well were infected with a series of diluted viruses in a 96-well flat-bottom plate. Cells were lysed with Promega lysis buffer at 48 h.p.i. Luciferase levels were measured using the Luciferase Assay System (Promega, Madison, WI, USA). Experiments were performed in triplicate and repeated twice. Fold changes in the decreases of infectivity (FC) were represented as relative EC50, which is the amount of virus (previously quantified using p24 and RT assays) needed for TZM-bl cells to produce half of the maximal level of luciferase in an infection.
Replication capacity assay
Thirty thousand PM1 cells were infected with 18 ng of p24 for each virus. Briefly, cells were incubated with viruses for 1 h at 37 °C. After incubation, cells were washed to remove unbound viruses and seeded in 96-well plates. Cell-free medium containing viruses was withdrawn for p24 measurements at days 3 and 7 p.i. The same volumes of fresh medium and new cells were added at each time point. Experiments were done in triplicate and each study of RT mutated viruses was performed separately.
Determination of integrated-HIV DNA
A total of 2 × 105 PM1 cells were infected with 125 ng p24. Cellular DNA was extracted at 48 h.p.i., using a DNeasy blood and tissue kit (Qiagene). A two-step Alu-gag PCR was performed as previously described . The first-round PCR was performed with a 65 ng DNA sample in a 25 µl reaction with primers Alu-F: 5′-GCCTCCCAAAGTGCTGGGATTACAG-3′ and Gag-R: 5′-GTTCCTGCTATGTCACTTCC-3′. The first cycle conditions were: 95 °C for 2 min, followed by 40 cycles of 95 °C for 15 s, 50 °C for 15 s, 72 °C for 3 min 30 s, and final elongation was at 72 °C for 5 min. The second-nested PCR was performed on a Corbett Rotor-Gene 6000 thermocycler, using Platinum quantitative PCR (qPCR) SuperMix-UDG (Invitrogen) with 5 µl of first-round PCR product in a 20 µl reaction. The primer sequences were LTR-F: TTAAGCCTCAATAAAGCTTGCC and LTR-R: GTTCGGGCGCCACTGCTAGA with the following cycle conditions: 50 °C for 2 min, 95 °C for 2 min, 60 cycles of 95 °C for 10 s, 60 °C for 10 s and 72 °C for 45 s. All samples were normalized in terms of β-globin content. The levels of integration are relative to WT virus at 0 h post infection.
Each experiment was repeated twice using three replicate samples each time. Data analyses including linear and non-linear regressions, and determinations of EC50, standard deviation, 95 % confidence intervals, and relative FC were calculated using GraphPad Prism 5.0 software. We used two-tailed Student’s t test with a 0.05 cut-off point to compare the best-fit values or means of each pair of different data sets.
HTP performed experiments and wrote the first version of the manuscript including figures. HTP and TM contributed to study designs, analyzed and interpreted data. MAW supervised the study and provided grant support needed for its implementation. He also contributed to the writing of the manuscript. All authors reviewed and finalized the final version before submission. All authors read and approved the final manuscript.
This work was funded by The Canadian Institutes of Health Research. HTP is the recipient of a Canadian HIV Trials Network Postdoctoral Fellowship. We thank Susan Germinario, Maureen Oliveira, Ilinca Ibanescu for technical assistance and Ying-Shan Han for helpful suggestions. We thank Hongtao Xu and Diane Singhroy for providing some of the plasmids used in this study. We thank Estrella Moyal for help with manuscript preparation.
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Mesplede T, Wainberg MA. Resistance against integrase strand transfer inhibitors and relevance to HIV persistence. Viruses. 2015;7:3703–18.View ArticlePubMedPubMed CentralGoogle Scholar
- Kandel CE, Walmsley SL. Dolutegravir—a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Des Dev Ther. 2015;9:3547–55.View ArticleGoogle Scholar
- Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses MA, Kilby JM, Lutz T, Podzamczer D, Portilla J, et al. Brief report: dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. J Acquir Immune Defic Syndr. 2015;70:515–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Molina JM, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K, Kulagin V, Givens N, de Oliveira CF, Brennan C, FLAMINGO Study Team. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015;2:e127–36.View ArticlePubMedGoogle Scholar
- Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13:927–35.View ArticlePubMedGoogle Scholar
- Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase–inhibitor–naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382:700–8.View ArticlePubMedGoogle Scholar
- Mesplede T, Osman N, Wares M, Quashie PK, Hassounah S, Anstett K, Han Y, Singhroy DN, Wainberg MA. Addition of E138K–R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. J Antimicrob Chemother. 2014;69:2733–40.View ArticlePubMedPubMed CentralGoogle Scholar
- Mesplede T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, Petropoulos CJ, Huang W, Wainberg MA. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology. 2013;10:22.View ArticlePubMedPubMed CentralGoogle Scholar
- Quashie PK, Mesplede T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol. 2012;86:2696–705.View ArticlePubMedPubMed CentralGoogle Scholar
- Wares M, Mesplede T, Quashie PK, Osman N, Han Y, Wainberg MA. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology. 2014;11:7.View ArticlePubMedPubMed CentralGoogle Scholar
- Huang W, Frantzell A, Fransen S, Petropoulos CJ. Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir. Antimicrob Agents Chemother. 2013;57:4105–13.View ArticlePubMedPubMed CentralGoogle Scholar
- Hurt CB, Sebastian J, Hicks CB, Eron JJ. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009–2012. Clin Infect Dis. 2014;58:423–31.View ArticlePubMedPubMed CentralGoogle Scholar
- Grobler JA, Hazuda DJ. Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences. Curr Opin Virol. 2014;8:98–103.View ArticlePubMedGoogle Scholar
- Anstett K, Mesplede T, Oliveira M, Cutillas V, Wainberg MA. Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions. J Virol. 2015;89:4681–4.View ArticlePubMedPubMed CentralGoogle Scholar
- Liang J, Mesplede T, Oliveira M, Anstett K, Wainberg MA. The combination of the R263K and T66I resistance substitutions in HIV-1 integrase is incompatible with high-level viral replication and the development of high-level drug resistance. J Virol. 2015;89:11269–74.View ArticlePubMedPubMed CentralGoogle Scholar
- Singhroy DN, Wainberg MA, Mesplede T. Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity. Antimicrob Agents Chemother. 2015;59:2882–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Iyidogan P, Anderson KS. Current perspectives on HIV-1 antiretroviral drug resistance. Viruses. 2014;6:4095–139.View ArticlePubMedPubMed CentralGoogle Scholar
- Sluis-Cremer N, Wainberg MA, Schinazi RF. Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection. Future Microbiol. 2015;10:1773–82.View ArticlePubMedGoogle Scholar
- Clumeck N, Molina JM, Henry K, Gathe J, Rockstroh JK, DeJesus E, Wei X, White K, Fordyce MW, Rhee MS, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65:e121–4.View ArticlePubMedGoogle Scholar
- Wohl DA, Cohen C, Gallant JE, Mills A, Sax PE, Dejesus E, Zolopa A, Liu HC, Plummer A, White KL, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65:e118–20.View ArticlePubMedGoogle Scholar
- Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, Rodgers AJ, Walker ML, Miller M, DiNubile MJ, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013;63:77–85.View ArticlePubMedGoogle Scholar
- Andreatta KN, Miller MD, White KL. Drug susceptibility and viral fitness of HIV-1 with integrase strand transfer inhibitor resistance substitutions Q148R or N155H in combination with nucleoside/nucleotide reverse transcriptase inhibitor resistance substitutions. Antimicrob Agents Chemother. 2015;60:757–65.View ArticlePubMedGoogle Scholar
- Andreatta KN, Goodman DD, Miller MD, White KL. Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations. Antimicrob Agents Chemother. 2015;59:3441–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Turner D, Brenner B, Wainberg MA. Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1. Clin Diagn Lab Immunol. 2003;10:979–81.PubMedPubMed CentralGoogle Scholar
- Delaunay C, Brun-Vezinet F, Landman R, Collin G, Peytavin G, Trylesinski A, Flandre P, Miller M, Descamps D. Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021). J Virol. 2005;79:9572–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Kosakovsky Pond SL, Chung YS, Penugonda S, Chipman JG, Fletcher CV, et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature. 2016;530:51–6.View ArticlePubMedGoogle Scholar
- Xu HT, Oliveira M, Quan Y, Bar-Magen T, Wainberg MA. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function. J Antimicrob Chemother. 2010;65:2291–9.View ArticlePubMedGoogle Scholar
- Wang J, Bambara RA, Demeter LM, Dykes C. Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions. J Virol. 2010;84:9377–89.View ArticlePubMedPubMed CentralGoogle Scholar
- Diallo K, Marchand B, Wei X, Cellai L, Gotte M, Wainberg MA. Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity. J Virol. 2003;77:8621–32.View ArticlePubMedPubMed CentralGoogle Scholar
- Sharma PL, Crumpacker CS. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. J Virol. 1997;71:8846–51.PubMedPubMed CentralGoogle Scholar
- Oliveira M, Mesplede T, Quashie PK, Moisi D, Wainberg MA. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS. 2014;28:813–9.View ArticlePubMedGoogle Scholar
- Xu HT, Martinez-Cajas JL, Ntemgwa ML, Coutsinos D, Frankel FA, Brenner BG, Wainberg MA. Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance. Retrovirology. 2009;6:14.View ArticlePubMedPubMed CentralGoogle Scholar
- Xu HT, Asahchop EL, Oliveira M, Quashie PK, Quan Y, Brenner BG, Wainberg MA. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol. 2011;85:11300–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Donahue DA, Bastarache SM, Sloan RD, Wainberg MA. Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses. J Virol. 2013;87:9620–32.View ArticlePubMedPubMed CentralGoogle Scholar